Calumet (CLMT): The $96 Million Loss Is Accounting, Not a Business

Calumet reported a $95.9 million net loss for Q2 2026 and shares fell on the print. The headline number looks like a reason to stay away. But strip out the non-cash regulatory accounting that is doing the heavy lifting on the income statement, and the company's adjusted EBITDA nearly tripled year-over-year to $159.3 million, its restricted-group leverage ratio fell below 4x, and it retired $115 million of high-cost debt in the month after quarter-end. The issue is not whether Calumet is losing money — the issue is whether the business underneath the accounting can compound its way out of a debt pile that has defined the stock for a decade.

The Operating Story

Revenue jumped 40.8% year-over-year to $1.445 billion, blowing past the $1.11 billion Wall Street expected. That growth came from volume and pricing in the Specialty Products and Solutions segment, which delivered $161.7 million in adjusted EBITDA — up from $66.8 million a year ago. Adjusted gross profit per barrel in that segment more than doubled, from $13.81 to $32.25, fueled by a global shortage in specialty products, higher production (62,903 barrels per day versus 55,703 a year ago), and what management called excellent commercial execution.

Montana Renewables, the company's sustainable aviation fuel and renewable diesel facility, turned from a $5.1 million adjusted EBITDA loss to $10.7 million of profit, or $26.6 million when you include federal clean fuel production credits — government tax credits that reward renewable fuel output. The facility completed its first phase of the MaxSAF 150 expansion and restarted in early May after a planned turnaround. That turn-from-red-to-green matters because Montana Renewables was the segment most investors worried would drag Calumet's cash flow for years.

Performance Brands, which includes the TruFuel consumer line, was the weak link. Adjusted EBITDA fell to $6.3 million from $13.5 million a year ago, as feedstock costs rose immediately while customer price increases lagged behind. There was also a $7.3 million LIFO (last-in-first-out inventory accounting) charge. That said, TruFuel volumes hit a record for the quarter. The margin compression here is a timing mismatch, not a demand problem.

Across all three segments, total facility production reached 83,191 barrels per day. The asset is running, and it is running profitably.

The $163.6 Million Distortion

Here is why Calumet shows a net loss despite that operating improvement. Roughly $163.6 million of the net loss came from renewable identification number charges — federal compliance credits that refiners must hold or purchase to prove their fuel meets renewable content mandates. The current RINs obligation on the balance sheet ballooned to $480.2 million from $169.3 million at year-end 2025. That is a real liability, and it is a real risk, but it is a regulatory accounting mechanic, not a reflection of operational performance.

GAAP EBITDA before adjustments was negative $30.3 million. The $159.3 million adjusted EBITDA that investors care about adds back those RINs charges along with other non-cash and non-recurring items. The spread between GAAP and adjusted numbers is wide — wider than most midstream or refining peers — and it means earnings-per-share figures at Calumet are almost useless as a standalone signal.

The RINs dynamic works both ways. When RINs prices fall, the obligation unwinds. Calumet is also a net generator of renewable fuel credits through Montana Renewables, which partially offsets its RINs buying obligation on the fossil-fuel side. The trajectory of that net position through 2026 and 2027 is one of the key variables nobody has clean visibility on yet.

Debt, Cash Flow, and the Leverage Gate

Calumet carries $2.259 billion in total debt and $109.8 million in cash. That is the starting point. The restricted-group leverage ratio — a covenant-based measure of net debt to EBITDA that matters more than headline leverage because it governs what the company can actually do — fell below 4x in Q2. Management expects it to drop below 3x in Q3, which would unlock meaningful financial flexibility.

Q2 operating cash flow exceeded $90 million. That sounds modest until you factor in that the quarter included roughly $70 million of working-capital buildup: about $30 million in intentionally higher crude inventory (a defensive move amid global oil market volatility), $30 million in receivables tied to higher specialty product pricing, and $20 million at Montana Renewables from post-expansion ramp-up. Management characterized these as timing items expected to unwind, which is fair but unproven. If they do not, cash conversion slows.

First-half operating cash flow was $6.1 million on $51.5 million of capital expenditures, producing free cash flow of negative $45.4 million for the six months. That is not the compounding engine of a quality holder like Visa or Microsoft. This is a leveraged refinery trying to generate enough cash to reduce its debt ratio without diluting shareholders.

The $115 million of debt retirement in July — $100 million of 9.75% senior notes redeemed at 102.4% plus $15.5 million on a Montana terminal financing — is the right move. Eliminating 9.75% debt when most of Calumet's remaining obligations sit at lower rates improves the interest-cost profile. Quarterly interest expense was $52 million, or about $208 million annualized. Against an annualized adjusted EBITDA run rate of roughly $637 million (four times Q2), interest coverage is approximately 3.1x. Manageable, but not cushy.

Valuation

Calumet shares trade around $41, with a market cap of approximately $3.6 billion. Analyst price targets cluster near $36.75 to $39.60 — below the current price, which suggests the sell-side has not fully priced in the Q2 operating inflection.

There is no clean trailing P/E to anchor on because GAAP earnings are deeply distorted by RINs. Looking at enterprise-value-to-EBITDA gives a clearer picture. With roughly $2.26 billion in debt, $110 million in cash, and $480 million in RINs obligations (which function as a financial liability), enterprise value is somewhere near $3.2 billion. Against a Q2 run-rate EBITDA of $637 million annualized, that implies roughly 5x EV/EBITDA. For comparison, peer refiner Delek Us Holdings trades at 7.9x EV/EBITDA, and Par Pacific trades at just 3.1x. Calumet sits between the two — not cheap by Par Pacific standards, not expensive relative to Delek.

The valuation question is whether Q2's EBITDA is sustainable or a cyclical peak. The global specialty-products shortage that drove SPS margins does not last forever. When crude prices normalize and the shortage eases, gross profit per barrel will compress. The question is whether the new floor — post-Montana, post-expansion — is still above what it takes to service $2 billion of debt and slowly pay it down.

The Thesis

This is not a quality compounder. Calumet is a cigar butt with a growth option attached. The hard-to-replace asset is a network of small, regional refineries that process low-value crude into specialty products — infrastructure that cannot be rebuilt overnight. The growth option is Montana Renewables, which is already generating positive adjusted EBITDA after completing its SAF expansion and which holds offtake agreements ahead of schedule.

The bear case is real: RINs obligations have tripled in six months, the specialty-products margin environment is cyclical, working-capital conversion has been weak, and $2.26 billion of debt on a $3.6 billion market cap is a lot of leverage for a commodity-adjacent business. If crude prices collapse, if RINs costs persist, or if the specialty-products shortage reverses faster than expected, the leverage becomes a trap.

The bull case is that the operating inflection is genuine, deleveraging is on track, the leverage ratio crosses below 3x in the next quarter unlocking covenant flexibility, and Montana Renewables becomes a durable profit center. At roughly 5x EV/EBITDA, the market has not priced that trajectory in yet.

Rating: Buy. The valuation gap between current price and the cash-flow improvement underway is real, and the debt gate — while narrow — remains intact. This is a position for investors who can tolerate volatility and understand that RINs distortion will keep GAAP earnings ugly for quarters to come. The key invalidation condition: if the restricted-group leverage ratio fails to move below 3x in Q3, or if operating cash flow does not convert as management expects, the thesis weakens materially.